Avadel Pharmaceuticals plc

Avadel is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.

Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy.